Ebola Cases Surpass 4,000 in DRC as WHO Calls for Vaccine Trials

The Democratic Republic of the Congo (DRC) has reported over 4,000 cases of Ebola amid the Bundibugyo strain outbreak, marking it as the world's second-largest and fastest-spreading epidemic of its kind. The World Health Organization (WHO) has responded by urging the initiation of controlled trials for the Ervebo vaccine, which remains the only licensed Ebola vaccine.
As of August 4, 2026, the DRC's national public health institute reported 3,973 cases and 1,801 deaths, with numbers continuing to rise. The WHO has issued guidance that Ervebo should not be used programmatically against the Bundibugyo virus due to insufficient evidence of its efficacy, recommending its application solely within research settings.
In response to the outbreak, the Oxford Vaccine Group launched the first Phase I clinical trial targeting the Bundibugyo ebolavirus on July 13, 2026. This trial, along with ongoing research into other potential treatments, such as the antiviral obeldesivir and antibody treatments like MBP134, represents a significant step in addressing the epidemic.
The WHO declared the outbreak a Public Health Emergency of International Concern (PHEIC) on May 17, 2026. This declaration underscores the urgency of developing effective vaccines and treatments, as Bundibugyo-specific outbreaks are rare and no licensed countermeasures currently exist.